Taysha gene therapies provides update on tsha-120 program in giant axonal neuropathy (gan)

Following type c meeting feedback from the u.s. fda, taysha is discontinuing development of tsha-120 in gan due to challenges with study design feasibility for potential biologics license application (bla) submission
TSHA Ratings Summary
TSHA Quant Ranking